Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
The clinical feasibility of 18F-LN1 PET/CT will be evaluated in 30 patients with urothelial carcinoma, and the results will be compared with those of 18F-FDG.
Sponsor:
Sichuan Provincial People's Hospital
Contacts:
Hao Wang, Doctor474556259@qq.com
+86-18313820216
Government Study Link:
NCT06120413 - Click here to see study onClinicalTrials.gov
Help us improve your experience